Visceral Adipose Tissue (VAT): Which Tests to Order Alongside

What Visceral Adipose Tissue Actually Measures

DEXA-derived VAT quantifies the fat mass stored between and around the abdominal organs, distinct from the subcutaneous fat sitting just beneath the skin. This distinction matters clinically because visceral fat is metabolically active in ways subcutaneous fat is not: it releases free fatty acids directly into the portal circulation and secretes pro-inflammatory adipokines including TNF-alpha, IL-6, and resistin. A 2012 analysis in Obesity Reviews confirmed that VAT, not total body fat, drives the dyslipidemia and insulin resistance pattern most associated with type 2 diabetes and cardiovascular events.

DEXA machines equipped with a CoreScan or equivalent algorithm output VAT area in cm² or VAT mass in grams. CT remains the reference standard for VAT quantification, but DEXA is preferred in routine clinical practice because it uses far less radiation.

How DEXA VAT Differs From Waist Circumference

Waist circumference is a proxy. Two patients with identical 40-inch waists may have vastly different VAT burdens depending on their subcutaneous-to-visceral fat ratio. The American Association of Clinical Endocrinology (AACE) 2016 obesity guidelines explicitly recommend body-composition analysis beyond waist circumference when metabolic risk stratification is the goal. DEXA VAT gives a direct depot-specific number that waist tape cannot provide.

VAT vs. Total Body Fat Percentage

Total body fat percentage captures subcutaneous depots that carry much lower metabolic risk. A lean-appearing patient with a normal BMI but elevated DEXA VAT above 100 cm² is sometimes called "metabolically obese, normal weight." A 2008 paper in Circulation (N=6,809) showed this phenotype carried the same cardiovascular event rate as classically obese patients, independent of BMI.

Normal VAT Range: What the Numbers Mean

A VAT area below 100 cm² is the most widely cited low-risk threshold in published literature. The 100 cm² cutpoint originates from CT-based studies correlating VAT area with insulin resistance, hypertension, and dyslipidemia clustering. Despres et al. In the American Journal of Cardiology (2008) placed the clinically significant threshold at 100 cm² for both sexes, though women tend to accumulate less absolute VAT for the same metabolic risk.

Sex-Specific Considerations

Men and women deposit fat differently. Premenopausal women preferentially store fat subcutaneously, which is hormonally regulated. After menopause, estrogen withdrawal shifts fat distribution centrally. A 2021 study in Menopause (N=509) found postmenopausal women had 49% higher VAT volume than age-matched premenopausal women. This means a VAT area of 90 cm² carries different clinical weight in a 55-year-old postmenopausal woman than in a 30-year-old woman with normal estrogen levels.

Age Trajectories

VAT increases with age independent of total body weight. Men accumulate VAT most rapidly between ages 30 and 50. Women see the steepest rise in the five years following menopause. The Framingham Heart Study offspring cohort documented a 36% increase in VAT over six years in middle-aged adults who maintained stable body weight, underscoring that weight stability does not guarantee VAT stability.

The Core Metabolic Panel to Order Alongside VAT

No single VAT number tells a complete story without knowing what that fat depot is actually doing to glucose metabolism, lipids, and systemic inflammation. The following tests convert a VAT result into a risk profile with treatment implications.

Fasting Insulin and HOMA-IR

Fasting insulin is the first metabolic test to add. Elevated VAT is the dominant driver of peripheral insulin resistance, and fasting insulin quantifies that resistance before HbA1c rises. HOMA-IR (fasting insulin in µU/mL × fasting glucose in mg/dL ÷ 405) above 2.5 indicates insulin resistance in most reference ranges. A 2020 Diabetes Care analysis confirmed HOMA-IR tracks VAT-associated insulin resistance more sensitively than fasting glucose alone. Order both together: fasting insulin and fasting plasma glucose drawn simultaneously after an 8-hour fast.

HbA1c and Fasting Glucose

HbA1c reflects 90-day average glucose and identifies prediabetes (5.7-6.4%) or diabetes (≥6.5%) per ADA Standards of Medical Care 2024. Fasting glucose below 100 mg/dL is normal; 100-125 mg/dL is impaired fasting glucose. Pairing HbA1c with HOMA-IR catches patients whose HbA1c is still normal but whose fasting insulin has already begun climbing, the stage where lifestyle or pharmacologic intervention has the highest return.

Triglycerides and HDL-C

The triglyceride-to-HDL ratio is a reliable surrogate for small dense LDL particle concentration, which is the lipid pattern most linked to VAT. A ratio above 3.5 in a white patient or above 3.0 in a Black patient suggests atherogenic dyslipidemia. The INTERHEART study found the ApoB-to-ApoA1 ratio was the single strongest lipid predictor of myocardial infarction across 52 countries, which is why ApoB belongs on the same order as the standard lipid panel when VAT is elevated.

Lipid Sub-Fractionation: Going Beyond Standard LDL

Standard LDL-C calculated by Friedewald equation underestimates risk in patients with elevated VAT because these patients carry disproportionately more small dense LDL particles at any given LDL-C level.

ApoB

ApoB counts each atherogenic particle directly. One ApoB = one atherogenic lipoprotein particle, regardless of cholesterol content. The 2019 ESC/EAS Dyslipidemia Guidelines recommend ApoB as the preferred risk marker over LDL-C in insulin-resistant and metabolic syndrome patients. A target ApoB below 80 mg/dL corresponds roughly to LDL-C below 70 mg/dL, but the mapping is imprecise in VAT-high patients.

Non-HDL Cholesterol

Non-HDL cholesterol (total cholesterol minus HDL-C) captures VLDL plus LDL and does not require a fasting sample. The ACC/AHA 2018 Cholesterol Guideline uses non-HDL above 130 mg/dL as a risk-enhancing factor justifying statin initiation or intensification. This marker costs nothing extra when a standard lipid panel is already drawn.

Lipoprotein(a)

Lp(a) is genetically fixed and largely unaffected by VAT or lifestyle change. Order it once, at baseline. An Lp(a) above 50 mg/dL (or above 125 nmol/L) is an independent cardiovascular risk factor that may shift treatment thresholds, particularly for statin therapy or emerging RNA-based therapies. The 2022 ACC Expert Consensus on Lp(a) recommends universal Lp(a) screening at least once in every adult.

Inflammation Markers

VAT secretes IL-6, which drives hepatic CRP synthesis. Measuring systemic inflammation quantifies how actively the visceral depot is stressing the cardiovascular system.

hsCRP

High-sensitivity CRP below 1.0 mg/L is low risk; 1.0-3.0 mg/L is intermediate; above 3.0 mg/L is high risk, per AHA/CDC 2003 scientific statement. HsCRP above 3.0 mg/L in the setting of elevated VAT is an indication for statin consideration even when LDL-C is at goal, as demonstrated by the JUPITER trial (N=17,802) where rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with LDL-C below 130 mg/dL but hsCRP above 2.0 mg/L.

Uric Acid

Fasting uric acid is an underused metabolic marker. VAT correlates with hyperuricemia via fructose-driven purine synthesis and impaired renal urate clearance. A meta-analysis in PLoS Medicine found serum uric acid above 6.0 mg/dL in women and above 7.0 mg/dL in men associated with a 97% higher risk of metabolic syndrome. Adding uric acid costs under two dollars on most lab panels.

Liver Function and MASLD Screening

Visceral fat is the primary driver of metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). VAT elevation without a liver screen misses a common and underdiagnosed comorbidity.

ALT, AST, and GGT

ALT is the most sensitive marker for hepatocellular injury. GGT rises early in steatosis and is also sensitive to alcohol use, which must be distinguished. AASLD 2023 MASLD Practice Guidance recommends screening all patients with metabolic risk factors for steatotic liver disease using ALT plus imaging when ALT is above 19 U/L in women or above 30 U/L in men.

FIB-4 Score

FIB-4 = (age × AST) ÷ (platelet count × √ALT). A score below 1.30 makes advanced fibrosis unlikely. A score above 2.67 warrants hepatology referral for fibroscan or liver biopsy. FIB-4 uses labs already ordered in the metabolic screen and requires no additional blood draw.

Hormone Panel: The VAT-Hormone Axis

Sex hormones and cortisol regulate fat distribution. Hormonal abnormalities can both cause and perpetuate elevated VAT.

Testosterone and SHBG in Men

Low total testosterone and low sex hormone-binding globulin (SHBG) are both independently associated with visceral obesity. A 2013 study in the Journal of Clinical Endocrinology and Metabolism found that every 1 standard deviation decrease in total testosterone corresponded to a 6.5 cm² increase in VAT in men aged 40-79. SHBG below 25 nmol/L is a surrogate marker for insulin resistance and VAT accumulation even when total testosterone is technically normal.

Estradiol and Progesterone in Women

In perimenopausal and postmenopausal women, falling estradiol levels directly reduce lipoprotein lipase activity in subcutaneous depots, redirecting fat storage toward visceral sites. Estradiol below 30 pg/mL in a woman with elevated VAT suggests that menopausal hormone therapy may address both the symptom burden and the metabolic risk simultaneously. The KEEPS trial (N=727) showed that oral conjugated equine estrogen and transdermal estradiol both reduced HOMA-IR compared to placebo over 48 months.

Morning Cortisol and DHEA-S

Hypercortisolism, even subclinical, drives preferential visceral fat deposition. A morning cortisol drawn at 8 AM above 20 µg/dL with clinical signs warrants a 1 mg overnight dexamethasone suppression test to screen for Cushing syndrome. Conversely, DHEA-S below 100 µg/dL in adults under 50 is associated with accelerated VAT gain; a study in the Journal of Internal Medicine showed DHEA supplementation in elderly men reduced VAT area by 9.4 cm² over 6 months.

Thyroid Function

Hypothyroidism reduces lipolysis and basal metabolic rate, promoting fat gain preferentially in visceral depots. A TSH above 4.5 mIU/L should prompt free T4 measurement. Subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) is present in approximately 5% of adults per NHANES data cited by the ATA and may contribute to VAT accumulation even before overt symptoms appear.

Adipokines: Leptin and Adiponectin

Adipokines are hormones secreted by fat tissue. They are not standard first-line tests but add depth when phenotyping a complex patient.

Fasting Leptin

Leptin is secreted in proportion to fat mass and signals satiety to the hypothalamus. In VAT-high patients, leptin levels are chronically elevated and receptor signaling is blunted. Fasting leptin above 15 ng/mL in men or above 20 ng/mL in women alongside elevated VAT confirms leptin resistance. A 2019 review in Cell Metabolism documented that leptin resistance precedes weight gain in animal models, suggesting it is causal rather than merely correlative.

Adiponectin

Adiponectin is anti-inflammatory and insulin-sensitizing. Its levels fall as VAT rises. A fasting adiponectin below 4 µg/mL is associated with insulin resistance and MASLD progression. The Nurses' Health Study found that the highest quintile of adiponectin had a relative risk of type 2 diabetes of 0.28 compared to the lowest quintile (P<0.001), a 72% risk reduction.

The HealthRX VAT Paired-Lab Framework below organizes these tests into three ordering tiers so clinicians can sequence tests by priority and cost.

Tier 1: Order with every elevated VAT result

• Fasting insulin + fasting glucose (HOMA-IR calculation)
• HbA1c
• Lipid panel with ApoB and non-HDL
• ALT, AST, GGT
• TSH
• hsCRP (high sensitivity)
• Uric acid
• Morning cortisol (8 AM)

Tier 2: Order when Tier 1 abnormalities are present or clinical suspicion is high

• Free T4 (if TSH elevated)
• Total testosterone + SHBG + estradiol (sex- and age-appropriate)
• DHEA-S
• FIB-4 score (calculated from Tier 1 labs)
• Lp(a) if not previously measured
• 1 mg overnight dexamethasone suppression test (if AM cortisol >20 µg/dL)

Tier 3: Add for complex phenotyping or research-grade characterization

• Fasting leptin
• Fasting adiponectin
• LDL particle number (NMR) or sdLDL direct measurement
• OGTT with insulin levels (75 g glucose, 0 and 120-minute insulin)

How to Lower VAT: Evidence-Based Interventions

High VAT is modifiable. The following interventions have direct trial evidence for VAT reduction rather than total body fat reduction alone.

Caloric Deficit and Diet Quality

A sustained 500-750 kcal/day deficit reduces VAT preferentially over subcutaneous fat. PREDIMED-Plus (N=6,874) showed Mediterranean diet with energy restriction reduced waist circumference 2.1 cm more than Mediterranean diet alone at 12 months, consistent with VAT reduction. Low-carbohydrate diets reduce VAT faster in the short term due to insulin suppression reducing de novo lipogenesis.

Aerobic Exercise

150 minutes per week of moderate-intensity aerobic exercise (target 65-75% maximum heart rate) reduces VAT independent of weight loss. A randomized controlled trial in Obesity (N=196) showed aerobic exercise reduced VAT by 6.9% over 6 months with no caloric restriction, while resistance training alone produced no significant VAT change.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961). STEP-1 in the New England Journal of Medicine did not separately report VAT, but a sub-study using MRI confirmed preferential visceral fat loss at 40 weeks. Tirzepatide 15 mg weekly produced 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539), with visceral fat reduction proportionally greater than subcutaneous fat reduction in body-composition sub-analyses.

Testosterone Therapy in Hypogonadal Men

Testosterone replacement in men with total testosterone below 300 ng/dL and VAT elevation reduces VAT area. A 2013 meta-analysis in the European Journal of Endocrinology covering 6 RCTs found testosterone therapy reduced waist circumference by 1.63 cm and fasting insulin by 1.73 µU/mL versus placebo over 6-24 months.

Monitoring Protocol After Intervention

Recheck DEXA VAT and the full Tier 1 lab panel at 3 months if a pharmacologic agent has been started, and at 6 months if the intervention is lifestyle only. A VAT reduction of 5-10 cm² corresponds to clinically meaningful improvements in HOMA-IR and triglycerides in most published cohorts. If VAT does not fall by at least 5 cm² after 6 months of documented lifestyle adherence, re-examine the hormone panel for unaddressed cortisol, thyroid, or testosterone abnormalities before escalating therapy.

The Endocrine Society 2023 Obesity Pharmacotherapy Guidelines recommend reassessing body composition within 3 months of starting any weight-management drug to confirm the patient is responding and to adjust dosing.